The Competition Commission on 10 June 2013 has approved acquisition of a manufacturing facility of Unichem Laboratories by pharma firm Mylan Laboratories.
As per the deal Mylan will acquire the newly established manufacturing facility pharma company, Unichem located in a Special Economic Zone in Dhar district of Madhya Pradesh, from. It makes 'Finished Dosage Forms (FDFs).
It was after carrying out of the agreement between Mylan and Unichem on 11 March 2013, Mylan had approached CCI for its approval in April 2013.
Earlier it was observed that the planned acquisition by Mylan was with the objective to export products to be manufactured at the company facility. But, it was noted by the regulator that the deal is not going to affect any market in India as Mylan is neither acquiring any shares, voting rights or control in Unichem nor any brands or intellectual property rights from Unichem.
Mylan has 11 manufacturing facilities in India, of which 8 facilities are for manufacture of Active Pharmaceutical Ingredients (API) and two are for making FDFs. Whereas Unichem have seven manufacturing facilities in India, of which 2 facilities are for manufacture of APIs and five are for FDFs which form the core of its business.
As per the deal Mylan will acquire the newly established manufacturing facility pharma company, Unichem located in a Special Economic Zone in Dhar district of Madhya Pradesh, from. It makes 'Finished Dosage Forms (FDFs).
It was after carrying out of the agreement between Mylan and Unichem on 11 March 2013, Mylan had approached CCI for its approval in April 2013.
Earlier it was observed that the planned acquisition by Mylan was with the objective to export products to be manufactured at the company facility. But, it was noted by the regulator that the deal is not going to affect any market in India as Mylan is neither acquiring any shares, voting rights or control in Unichem nor any brands or intellectual property rights from Unichem.
Mylan has 11 manufacturing facilities in India, of which 8 facilities are for manufacture of Active Pharmaceutical Ingredients (API) and two are for making FDFs. Whereas Unichem have seven manufacturing facilities in India, of which 2 facilities are for manufacture of APIs and five are for FDFs which form the core of its business.
No comments:
Post a Comment